CJC-1295 vs PEG-MGF
Head-to-head comparison of CJC-1295 and PEG-MGF for research applications. Both peptides are studied for Body Composition, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Cjc 1295 | Peg Mgf |
|---|---|---|
| Category | Growth Hormone Secretagogue | Muscle & Performance |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous growth hormone, which in turn increases IGF-1 levels. | MGF is produced from the IGF-1 gene by alternative splicing of exons 4, 5, and 6. |
| Evidence Rating | D — Preclinical | D — Preclinical |
| Clinical Status | Research-only / Not approved for human use | Research-only. No human clinical trials registered or completed. Preclinical characterization primarily in cell culture and rodent models. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | No human clinical trials — safety profile is entirely unknown; No formal toxicology studies published for PEG-MGF |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~2,867 g/mol (peptide portion); total MW depends on PEG chain size |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | Native MGF: minutes; PEG-MGF: estimated several hours (no published human PK data) |
Overview
CJC-1295 and PEG-MGF are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
PEG-MGF — Mechanism & Evidence
PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of the C-terminal peptide of mechano growth factor (MGF), a splice variant of the IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents). Native MGF is expressed locally in skeletal muscle immediately following mechanical overload or damage (e.g., resistance exercise). It stimulates muscle satellite cell (stem cell) activation and proliferation, initiating the early repair response before the sustained IGF-1Ea isoform takes over for differentiation. Because native MGF has an extremely short half-life (minutes), PEGylation (conjugation with polyethylene glycol) protects the peptide from enzymatic degradation, extending systemic circulation. It is prohibited by WADA and not approved for human therapeutic use.
Key claims: Activates muscle satellite cells for repair; Promotes muscle hypertrophy; PEGylation extends duration of action.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
PEG-MGF is also researched for: Injury Recovery.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
PEG-MGF: No human clinical trials — safety profile is entirely unknown No formal toxicology studies published for PEG-MGF Theoretical oncogenic risk: satellite cell proliferation and IGF-1 pathway activation are relevant to cancer biology
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe